CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $244,546 | -5.4% | 4,356 | -23.8% | 0.23% | -4.1% |
| Q1 2023 | $258,625 | +11.3% | 5,718 | 0.0% | 0.24% | +22.7% |
| Q4 2022 | $232,437 | -37.9% | 5,718 | 0.0% | 0.20% | -43.8% |
| Q3 2022 | $374,000 | +4.2% | 5,718 | 0.0% | 0.35% | +27.5% |
| Q1 2022 | $359,000 | -29.2% | 5,718 | -14.5% | 0.28% | -23.3% |
| Q4 2021 | $507,000 | -43.7% | 6,687 | -16.8% | 0.36% | -49.2% |
| Q3 2021 | $900,000 | -30.0% | 8,037 | +1.2% | 0.71% | -28.6% |
| Q2 2021 | $1,286,000 | +33.5% | 7,943 | +0.5% | 0.99% | +25.4% |
| Q1 2021 | $963,000 | -26.0% | 7,901 | -7.1% | 0.79% | +79.1% |
| Q4 2020 | $1,302,000 | +32.5% | 8,505 | -27.6% | 0.44% | +7.6% |
| Q3 2020 | $983,000 | +41.8% | 11,748 | +24.6% | 0.41% | +15.5% |
| Q2 2020 | $693,000 | – | 9,428 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |